WO2002096405A1 - Preparations de medicaments - Google Patents
Preparations de medicaments Download PDFInfo
- Publication number
- WO2002096405A1 WO2002096405A1 PCT/JP2002/005041 JP0205041W WO02096405A1 WO 2002096405 A1 WO2002096405 A1 WO 2002096405A1 JP 0205041 W JP0205041 W JP 0205041W WO 02096405 A1 WO02096405 A1 WO 02096405A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- sodium
- acid
- oil
- hydrochloride
- powder
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid, pantothenic acid
- A61K31/198—Alpha-aminoacids, e.g. alanine, edetic acids [EDTA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
Definitions
- the present invention relates to a pharmaceutical combination, and more particularly, to a pharmaceutical combination which has an antitussive effect and an expectorant effect and can be advantageously used as an antitussive expectorant and the like.
- a pharmaceutical compound for colds often contains a component having an antitussive effect or a component having an expectorant effect.
- antitussive and expectorant drugs whose main purpose is antitussive and expectorant.
- the present inventors have studied various combinations of drugs having antitussive activity and other pharmaceutical ingredients to obtain a pharmaceutical combination having an excellent antitussive and expectorant action, and studied the effectiveness of the combination.
- fudostin which is useful as an expectorant, does not show an antitussive effect by itself, it has been found that combining this with a drug having an antitussive effect significantly enhances the antitussive effect of the antitussive, completed. That is, the present invention provides a pharmaceutical combination containing fudostin and a drug having an antitussive action.
- fudostin and an antitussive are combined as essential active ingredients.
- the fudostin used in the present invention is S- (3-hydroxypropyl) -L-cysteine represented by the following formula (I), and it has been reported that this is useful as an expectorant as disclosed in It is reported in 674.
- salts thereof for example, an inorganic acid salt, an organic acid salt, an alkali metal salt, and an alkaline earth metal salt of fudostin can be used.
- the amount of fudostin or a salt thereof in the pharmaceutical composition of the present invention is not particularly limited, but is generally about 12 mg to 240 mg as a daily dose for an adult, preferably one day for an adult. The amount is about 40 mg to 120 mg.
- the drugs having an antitussive action used in the pharmaceutical combination of the present invention include alkacrylamide hydrochloride, cloperastine hydrochloride, pentoxiverine citrate, thividin citrate, sodium dibutnate, dextromethorphan hydrobromide, dextromethorphan Tromethorphan phenolphthalic acid, thipididine hibenzate, cloperastine fendizoate, codine phosphate, dihydrocodine phosphate, trimethoquinol hydrochloride, phenylpropanolamine hydrochloride, methoxyphenamine hydrochloride, d I—Methylephedrine hydrochloride, I—Methylephedrine hydrochloride, Noscapine hydrochloride, Noscapine, Mao, Nanami, d I Monomethylephedrine saccharin salt, Carbeta pentane citrate, Dimemorphuan phosphate, Benprop
- the amount of the drug having an antitussive action in the pharmaceutical combination drug of the present invention can be determined according to the known compounding method, depending on the type and amount of other drugs used together, but is usually 1 mg to 1 mg / day for an adult. It is in the range of 20 g, and preferably 1.2 mg to 10 g as a daily adult dose.
- the pharmaceutical combination of the present invention may further contain other medicinal ingredients in addition to the above essential ingredients.
- medicinal ingredients include one or more selected from bronchodilators, antihistamines, stimulants, crude drugs, antacids or mucosal protective agents, and bactericides.
- bronchodilators include aminophylline, diprofilin, theophylline, proxyphylline, choline theophylline, epinephrine, ephedrine hydrochloride, isoprenaline sulfate, isoprenaline hydrochloride, orciprenaline sulfate, chlorprenaline hydrochloride, salbutamol sulfate, salbutamol sulfate, Terbutaline sulfate, robuterol hydrochloride, propoterol hydrochloride, phenotere hydrobromide, formoterol fumarate, clenbuterol hydrochloride, mappterol hydrochloride, pipum bromide plume, plume bromide plumum, pumium bromide plume , Pumium bromide, salmeterol xinarate, hexoprenaline sulfate, Ro
- the amount of the bronchodilator is determined according to the known formulation method, depending on the type and amount of other drugs to be used together, but it is generally in the range of 1 Otg to 1 OO Omg as a daily dose for adults.
- the daily dose for an adult is 42 mg to 60 Omg.
- antihistamines examples include isotipendyl hydrochloride, iproheptin hydrochloride, diphthelol hydrochloride, dipheniravirine hydrochloride, diphenhydramine hydrochloride, triprolidine hydrochloride, tririvenamine hydrochloride, tondylamine hydrochloride, phenetazine hydrochloride, promethazine hydrochloride, salicyline hydrochloride, and salicyline hydrochloride.
- the amount of the antihistamine to be combined is determined according to the known formulation method, based on the type and amount of the other drugs to be used together, but is usually in the range of 1 mg to 30 Omg per day for adults. Preferably, the daily dose for an adult is 3 mg to 150 mg.
- stimulants include sodium benzoate, caffeine, caffeine, hydrodynamic phenine, dI—methylephedrine hydrochloride, dI—methylephedrine saccharin salt, ephedrine hydrochloride, phenylpropanolamine hydrochloride, and phene.
- I methylephedrine hydrochloride, methoxyphenamine hydrochloride, d I—epinephrine hydrochloride, d I—isoproterenol hydrochloride, isoproterenol sulfate, orciprenaline sulfate, terbutaline sulfate, salvulinol sulfate, trimethoquinol hydrochloride, Hexoprenaline sulfate, chlorprenaline hydrochloride, rlobbuterol hydrochloride, proterol hydrochloride, pirbuterol hydrochloride, phenoterol hydrobromide, folmoterol fumarate, clenbuterol hydrochloride, mabuterol hydrochloride, ethilcysteine hydrochloride, salt Methyl cis Ting, pseudoephedrine and the like, and these alone or may be used in conjunction with two or more.
- the compounding amount of the stimulant is determined according to the known compounding method according to the type and amount of the other drugs to be used together, but is usually in the range of 1 to 90 Omg as a daily dose for adults, preferably, The daily dose for adults is 5 to 30 Omg.
- examples of crude drugs include: Mao, Minami Amami, Cherry bark, Enshi, Licorice, Kikyo, Almond, Kurumaeko, Karumae grass, Ishiru, Senega, Kakkon, Shellfish, Asenyaku, Fengka, Yellow Gon, Karonine , Cinnamon, goo, gomin, fine spicy, Shion, jiyako, ginseng, ginger, mulberry bark, soybean leaves, bamboo ginseng, cinnamon, ginseng, mushy winter, midsummer etc. These can be used alone or in combination of two or more.
- the amount of the crude drug is determined according to the known formulation method, based on the type and amount of other drugs to be used in combination.
- the daily dose for adults is 0.001 g to 300 g as extract (equivalent crude drug).
- g in the range of 0.0004 g to 60 g as a powder, preferably 0.005 g to 10 g as an extract (equivalent to crude drug) and 0.001 g to 3 g as a powder.
- examples of antacids or mucoprotectants include aminoaminoacetic acid, magnesium oxide, magnesium carbonate, magnesium silicate, synthetic aluminum silicate, synthetic hydrotalcite, dihydroaluminumaminoacetate, aluminum hydroxide gel, and dried Aluminum hydroxide gel, aluminum hydroxide ⁇ magnesium carbonate mixed dry gel, aluminum hydroxide ⁇ sodium bicarbonate coprecipitate, aluminum hydroxide-calcium carbonate ⁇ magnesium carbonate coprecipitate, magnesium hydroxide ⁇ potassium aluminum sulfate Precipitates, magnesium aluminate metasilicate, magnesium hydroxide, aluminum sulfate, sucralfate, etc., can be used alone or in combination of two or more.
- the amount of the antacid or mucosal protective agent is determined according to the known formulation method, depending on the type and amount of other drugs used in combination, but it is usually 1 Omg to 8000 mg per day for adults. Preferably, it is 100 mg to 4000 mg.
- fungicides examples include cetyl pyridium chloride, decalinium chloride, chlor hydrochloride Hexidine and the like can be mentioned, and these can be used alone or in combination of two or more.
- the amount of the fungicide is determined according to the known formulation method, depending on the type and amount of other drugs to be used in combination, but it is usually in the range of 0.05 mg to 5 O mg as a daily dose for adults. And preferably 0.1 to 25 mg to 5 mg.
- the pharmaceutical combination may further contain vitamins and anti-inflammatory enzyme drugs.
- vitamins include sultiamine, prosultiamine, fursultiamine, flusultiamine hydrochloride, bisbenthamine, benph thiamine, dicetiamine hydrochloride, sicotiamine, cocarboxylase, thiamine disulfide, thiamine hydrochloride, Vitamin B, such as thiamine nitrate, bisthiamine nitrate, thiamine dicetyl sulfate, bisibutiamine, and derivatives thereof, and salts thereof, vitamins such as riboflavin, riboflavin butyrate, sodium riboflavin phosphate, and flavin adenine dinucleotide sodium B 2 and its derivatives and salts such thereof, Asukorubin acid, Asukorubin San'naboku Liu ⁇ , vitamin C and its derivatives and their salts such as calcium Asukorubin acid, hesperidin and its derivative And their salts, vitamin A, such as vitamin F, retino
- the amount of vitamins to be compounded is determined according to the known combination method according to the type and amount of other drugs to be used together, but is usually in the range of 0.1 mg to 200 mg as a daily dose for adults. And preferably 1 mg to 50 O mg.
- anti-inflammatory enzyme drug examples include promelain, pronase, serapeptase, semi-alkaline proteinase, streptokinase, streptodornase, lysozyme chloride, etc., and these may be used alone or in combination of two or more. That it can.
- the amount of the anti-inflammatory enzyme drug is usually 4 mg to 300 mg, preferably 15 mg to 60 mg as a daily dose for an adult.
- the pharmaceutical combination of the present invention further includes expectorants other than fudostin, for example, potassium guaiacolsulfonate, guaifenesin, potassium iodide, ammonia ammonia, sodium bicarbonate, bromhexine hydrochloride, carbocistin, hydrochloric acid Amplifier mouth, methyl cysteine hydrochloride, acetyl cysteine, ethyl cysteine hydrochloride, ebrazinone hydrochloride, ammonium chloride, potassium cresol sulfonate, I-menthol, trimethinoquinol hydrochloride, phenylpropanolamine hydrochloride, methyl hydrochloride Trixyphenamine may be used alone or in combination of two or more. The amount of these expectorants is usually 1 mg to 300 mg, preferably 6 mg to 90 mg as a daily dose for adults.
- expectorants other than fudostin for example, potassium guaiacolsul
- the pharmaceutical combination according to the present invention comprises a tablet, granule, fine granule, powder, hard capsule, soft capsule, tablet, granule, fine granule, powder, Pills, troches, drops, suspensions, emulsions, oral liquids, syrups, dry syrups, inhalants, oral mucosal preparations, etc. It is prepared by Each medicinal component may be made into microparticles such as microcapsules, nanocapsules, microspheres, nanospheres, etc., and then the above-mentioned preparations may be prepared.
- the preparation of the pharmaceutical combination of the present invention is not particularly limited and can be carried out by various methods.
- commonly used granulation methods including water and organic solvents
- Wet granulation method such as spray granulation method using solution or dispersion, stirring granulation method, fluidized granulation method, tumbling granulation method, tumbling fluidized granulation method, and compaction granulation using powdery binder It is manufactured by a dry granulation method such as a method.
- the preparation is to be granules, fine granules or powders, powders or granules containing the active ingredient
- the powder can be mixed and subdivided into smaller packages to be filled.
- powder, granulated powder, small tablets, etc. are filled into capsules using a capsule filling machine. Is done.
- the powder of the active ingredient, powders, fine granules, granules and pills, and a pharmaceutical additive may be mixed and compression-molded.
- the pan-coating method, the fluid-coating method, the rolling coating method, and the combination of these coating agents into tablets and granules, etc. Just coat it.
- the coating agent can be dissolved and / or dispersed in water or an organic solvent and spray-coated, or the coating agent can be directly sprayed and dried by applying heat or pressure.
- the coating amount of the coating agent can be selected as needed depending on the dosage form and the like. Generally, tablets are about 0.1 to 100% by mass, pills and granules are about 0.1 to 200% by mass, and fine granules are about 0.1 to 300% by mass. It is.
- oral liquids such as syrups, elixirs, limonades, extracts and drinks, as well as soft capsules and hard capsules filled with liquid or semi-solid substances, usually have the respective active ingredients.
- a part of a solvent such as purified water are mixed / dissolved / dispersed, and the remaining solvent is added to adjust the amount of liquid to produce.
- the pH may be adjusted using an acid or an alkali.
- a fat-soluble component it may be solubilized, emulsified, or suspended by using formulation additives such as a surfactant, a solubilizer, an emulsifier, and a suspending agent. Heating, cooling, nitrogen replacement, filtration, sterilization, etc. may be applied as necessary during adjustment.
- a pharmaceutical additive may be used to stabilize, sustainedly release, sustain, rapidly disintegrate, rapidly dissolve, improve the solubility of the active ingredient, improve the solubility, mask the taste, A function such as improvement of a feeling of taking may be added.
- Methods for adding these functions can be performed by commonly used methods, for example, compounding the active ingredient into separate granules, forming a multi-layer granule, a multi-layer tablet or a dry coated tablet, Tableting into separate granules Method, microcapsules, sugar-coated tablets, film-coated tablets, coated granules, etc., foamed formulations, chewable formulations, orally disintegrating formulations, matrices Method, co-grinding method, solid solution method, adding sweetener and freshener, adding antioxidant and stabilizing agent, specific PH, viscosity, osmotic pressure, salt concentration Various methods such as an adjusting method can be cited, and these methods may be combined.
- Pharmaceutically acceptable pharmaceutical additives used in the production of the pharmaceutical combination of the present invention include stabilizers, stabilizers, surfactants, plasticizers, lubricants, lubricants, solvents, and solvents.
- excipients, bases, and fillers are DL-alanine, dI-malic acid, D-Sorbi! ⁇ Il, D-Sorbi! ⁇ Il solution, D-mannitol, L 1-aspartic acid, L-glutamine,) 8-cyclodextrin, aminoethylsulfonic acid, gum powder, gum arabic, gum arabic, alginic acid, sodium alginate, propylene glycol alginate, alpha-starch starch, wild boar!
- solvent solubilizing agent, solubilizing agent, and solubilizing agent
- solubilizing agent examples include dl-camphor, D-mannitol, D-sorby! ⁇ -L, D-sorbitol solution, L-aspartic acid, L-aspartic acid, and L-aspartic acid.
- disintegrants examples include D-sorbitol, D-manni! ⁇ -Yl, adipic acid, aminoalkyl methacrylate tricopolymer RS, gum arabic, Gum arabic, alginic acid, sodium alginate, propylene delicol alginate, alpha-monostarch, ethanol, ethyl cellulose, crude rib oil, oleic acid, carboxyvinyl polymer, sodium carboxymethyl starch, carmellose, Carmellose calcium, carmellose sodium, powdered agar, powdered agar, guar gum, citrate, calcium citrate, sodium citrate, glycerin, glycerin fatty acid ester, croscarmellose sodium, crospovidone, magnesium silicate, Wheat starch, rice starch, choline phosphate, safflower oil, beeswax, di-oct
- pH adjusting agent examples include dI-monomalic acid, D-sorbyI ⁇ l, D-sorbi! ⁇ l solution, D-mannii! ⁇ l, D-tartaric acid, magnesium L-aspartate, L-arginine, L-glutamic acid, sodium L-glutamate, adipic acid, ascorbic acid, aminoethylsulfonic acid, xylitol, culic acid, calcium citrate, calcium citrate Sodium, sodium citrate, glycine, glycerin, darcono (5-lactone, calcium dalconate, succinic acid, sodium succinate hexahydrate, nicotinamide, glucose, sodium fumarate , Propylene glycol, sodium polyphosphate, macrogol 400, maleic acid, sodium metaphosphate, phosphoric acid, dipotassium phosphate, phosphoric acid Trisodium, sodium hydrogen phosphate, potassium dihydrogen
- surfactants include D-sorbitol, ethanol, carrageenan, carboxyvinyl polymer, carmellose sodium, guar gum, glycerin, glycerin fatty acid ester, cholesterol, and salamitsu.
- Wetting agents ⁇ Wetting regulators, binders, suspending agents, thickeners, thickeners, adhesives, adhesion enhancers, softeners, and plasticizers are specific examples of D-sorbitol and D-sorbi! ⁇ One solution, D-manni!
- coating agents include 2-methyl-5-vinylpyridine methyl acrylate, methacrylic acid copolymer, dI-malic acid, and D-sorby. Toluol, D-sorbitol solution, D-manni!
- stabilizers examples include adipic acid, DL-alanine, dI-camphor, D-sorbi! ⁇ I solution, d-polneol, D-sorbi I , D-mannyl, L-ascorbic acid stearate, Sodium L-ascorbate, L-aspartic acid, sodium L-aspartate, L-arginine, I-menthol, jS-cyclodextrin, ascorbic acid, aminoethylsulfonic acid, sodium alginate, propylene glycol alginate Ester, albumin, rosin, inositol, wick powder, ethanol, ethanol, calcium disodium edetrate, sodium edetate, erythorbic acid, sodium erythorbic acid, cocoa butter, carboxyvinyl polymer, carme Loose calcium, carmellose sodium, agar, x
- flavoring agents include 5'-inonatrium inosinate, disodium 5-guanylate, DL-aranan, dl-camphor, dI-menthol, dl-malic acid , D I-sodium malate, DL-sodium tartrate, d-camphor, D-xylose, D-sorbitol, D-sorbitol, d-borneol, D-mannitol, D-tartaric acid, L-asparagine Acid, sodium L-aspartate, magnesium L-aspartate, L-glutamate, L-glutamate, arginine, L-sodium glutamate, L-glutamate, I-men!
- adsorbent examples include kaolin, carmellose calcium, hydrous silicon dioxide, magnesium silicate, light anhydrous silicic acid, diatomaceous earth, crystalline cellulose, synthetic aluminum silicate, aluminum oxide, aluminum hydroxide, and magnesium carbonate. And calcium carbonate, dextrin, silicon dioxide, bentonite, magnesium aluminate metasilicate, medicinal charcoal and the like.
- antifoaming agents include ethanol, glycerin fatty acid ester, dimethylpolysiloxane (for internal use), dimethylpolysiloxane and silicon dioxide mixture, sucrose fatty acid ester, silicone resin emulsion, silicone antifoaming agent, polyoxyl stearate. 40, sorbitan fatty acid ester, sorbitan trioleate, polysorbate 80 and the like.
- mastication agent examples include d-borneol.
- coloring agent examples include asphalt tannin powder, cocoon extract, yellow iron trioxide, Ospray K-124, orange essence, brown iron oxide, potato black, and caramel. , Carmine, carotene solution,) 8-carotene, kanzo kiss, gold leaf, black iron oxide, light caffeic anhydride, titanium oxide, iron sesquioxide, edible blue No. 1, edible yellow No. 4, edible yellow No. 4 aluminum lake, edible Yellow No. 5, Food Red No. 2, Food Red No. 3, Food Red No.
- 102 Sodium Hydroxide, Talc, Copper Cloth Filinna Triumum, Copper Chlorophyll, Green Leaf Extract Extract, d-Borneol Octyldodecyl myristate, medicinal charcoal, riboflavin butyrate, riboflavin, green tea powder, sodium riboflavin phosphate, rose oil, etc.
- the soothing agent include inositol, sodium hydrogen carbonate, radish oil, glucose, propylene glycol, lidocaine and the like.
- the pharmaceutical combination of the present invention obtained as described above is characterized in that fudostin contained in the combination acts on a drug having an antitussive effect and enhances its effect.
- Combination drug for colds Very useful as an antitussive expectorant. ! ⁇
- Test example 1
- Hartley male guinea pigs of 300 to 400 g in groups of 5 animals were used as experimental animals.
- Miyata et al. Method (Arch. Lnt.Pharmacodyn.Ther. No. 304, pp. 277 pp., 1990) according to the S0 2 gas, 2 hours a day at exposure apparatus, exposure to guinea pig Bok to continue communicating 8 days To make guinea pigs with airway inflammation.
- Guinea pigs were fixed under non-anesthesia chamber one, chamber Kabusaishin (1 0 6 mo I / L ) using an ultrasonic nebulizer one (TUR-3200, Nihon Kohden) on the day following the last exposure day of S0 2 gas Sprayed within for 2 minutes, causing a cough. The reaction was observed for 2 minutes during spraying and then for 13 minutes, for a total of 15 minutes. The number of coughs that occurred during this period was counted. (Result)
- Example 2 Using 200 g of fudostin, 60 g of dextromethorphan hydrobromide, 38 g of corn starch, 1 g of talc and 1 g of magnesium stearate, form tableting powders in a conventional manner, using a rotary tableting machine. A tablet of 8.5 mg in diameter and 250 mg per tablet was produced.
- Example 2 Using 200 g of fudostin, 60 g of dextromethorphan hydrobromide, 38 g of corn starch, 1 g of talc and 1 g of magnesium stearate, form tableting powders in a conventional manner, using a rotary tableting machine. A tablet of 8.5 mg in diameter and 250 mg per tablet was produced.
- Example 2 Example 2
- Granules were prepared in a conventional manner using 120 g of fudostin, 3 g of dihydrocodeine phosphate, 3.3 g of lysozyme chloride, 7.5 g of chlorpheniramine maleate, 89.7 g of corn starch and 83.25 g of trehalose.
- Example 5
Landscapes
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Pulmonology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP02726486A EP1391200A4 (en) | 2001-05-25 | 2002-05-24 | DRUG |
KR10-2003-7015166A KR20030097892A (ko) | 2001-05-25 | 2002-05-24 | 의약 배합제 |
US10/477,755 US20040147605A1 (en) | 2001-05-25 | 2002-05-24 | Drug preparations |
CA002448068A CA2448068A1 (en) | 2001-05-25 | 2002-05-24 | Drug preparations |
JP2002592916A JP4365106B2 (ja) | 2001-05-25 | 2002-05-24 | 医薬配合剤 |
HK05101542A HK1068812A1 (en) | 2001-05-25 | 2005-02-24 | Drug preparations |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001156853 | 2001-05-25 | ||
JP2001-156853 | 2001-05-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002096405A1 true WO2002096405A1 (fr) | 2002-12-05 |
Family
ID=19000798
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2002/005041 WO2002096405A1 (fr) | 2001-05-25 | 2002-05-24 | Preparations de medicaments |
Country Status (9)
Country | Link |
---|---|
US (1) | US20040147605A1 (ja) |
EP (1) | EP1391200A4 (ja) |
JP (1) | JP4365106B2 (ja) |
KR (1) | KR20030097892A (ja) |
CN (1) | CN1293867C (ja) |
CA (1) | CA2448068A1 (ja) |
HK (1) | HK1068812A1 (ja) |
TW (1) | TW589177B (ja) |
WO (1) | WO2002096405A1 (ja) |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007153877A (ja) * | 2005-11-11 | 2007-06-21 | Daiichi Sankyo Healthcare Co Ltd | 去痰剤を含有する医薬組成物 |
JP2007197423A (ja) * | 2005-12-27 | 2007-08-09 | Daiichi Sankyo Healthcare Co Ltd | フドステインと抗コリン薬を含有する医薬組成物 |
JP2009001548A (ja) * | 2007-05-21 | 2009-01-08 | Daiichi Sankyo Healthcare Co Ltd | トレハロースからなる気道杯細胞過形成抑制剤。 |
JPWO2007018190A1 (ja) * | 2005-08-10 | 2009-02-19 | 塩野義製薬株式会社 | 苦味抑制製剤 |
JP2013035869A (ja) * | 2005-11-11 | 2013-02-21 | Daiichi Sankyo Healthcare Co Ltd | 去痰剤を含有する医薬組成物 |
JP2013082754A (ja) * | 2005-11-24 | 2013-05-09 | Boehringer Ingelheim Internatl Gmbh | テルミサルタン及び利尿剤を含有する二層錠剤 |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR101016595B1 (ko) | 2002-07-31 | 2011-02-22 | 센주 세이야꾸 가부시키가이샤 | 수성액제 및 광안정화된 수성액제 |
US8877168B1 (en) | 2002-07-31 | 2014-11-04 | Senju Pharmaceuticals Co., Ltd. | Aqueous liquid preparations and light-stabilized aqueous liquid preparations |
US20090270517A1 (en) * | 2005-03-31 | 2009-10-29 | Japan Scinece And Technology Agency | Emulsion With Tolerance to Alcohol and Process for Producing the Same |
KR101011278B1 (ko) * | 2005-07-22 | 2011-01-28 | 미쓰비시 타나베 파마 코퍼레이션 | 구강내 속붕괴성 정제 |
US20070092578A1 (en) * | 2005-10-26 | 2007-04-26 | Yasuhiro Itagaki | Skin rejuvinating supplement |
US7282224B1 (en) | 2006-06-09 | 2007-10-16 | Guthy-Renker Corporation | Pain relief composition |
WO2008046625A2 (en) * | 2006-10-18 | 2008-04-24 | Dsm Ip Assets B.V. | Encapsulation of heat and moisture sensitive substances |
US20080107747A1 (en) * | 2006-10-23 | 2008-05-08 | Roederer Joy E | Pain relief composition |
CA2732018C (en) * | 2008-07-31 | 2017-07-04 | Takeda Pharmaceutical Company Limited | Solid pharmaceutical composition |
WO2010116048A1 (fr) * | 2009-04-10 | 2010-10-14 | Sleimen Kettany | Composition à base de plantes pour le traitement ou la prévention de maladies virales du sang telles que les maladies causées par le virus de l' immunodéficience humaine (vih) ou l'hépatite c |
CN102188445B (zh) * | 2010-03-12 | 2012-10-31 | 上海延安药业有限公司 | 一种氨茶碱的复方制剂及其制备方法 |
US20120107395A1 (en) * | 2010-11-01 | 2012-05-03 | Viva Pharmaceutical Inc. | Probiotic Soft Gel Compositions |
CN103006656A (zh) * | 2011-09-26 | 2013-04-03 | 湖南九典制药有限公司 | 一种镇咳祛痰的复方化学药物 |
CN103006657B (zh) * | 2011-09-27 | 2016-02-10 | 湖南九典制药股份有限公司 | 一种含有愈创木酚的复方化学药物 |
HUE036187T2 (hu) | 2012-04-30 | 2018-06-28 | Tillotts Pharma Ag | Késleltetett leadású gyógyszerkészítmény |
WO2014087419A1 (en) * | 2012-12-06 | 2014-06-12 | Colgate-Palmolive Company | Oral gel for sensitivity and tooth pain |
UA117260C2 (uk) * | 2013-10-29 | 2018-07-10 | Тиллоттс Фарма АГ | Лікарський препарат з відстроченим вивільненням |
US9662367B2 (en) | 2014-08-01 | 2017-05-30 | Rubikon Ltd. | Adaptogenic compositions and method for production thereof |
CN104224765B (zh) * | 2014-09-03 | 2016-08-24 | 河北仁合益康药业有限公司 | 一种愈酚溴新口服溶液组合物 |
CN107007480B (zh) * | 2015-11-30 | 2021-08-17 | 富士胶片株式会社 | 凝胶状水包油型乳化组合物、皮肤外用剂以及水包油型乳化组合物的制造方法 |
CN109628401A (zh) * | 2018-11-20 | 2019-04-16 | 遵义医学院附属医院 | 一种非酒精性脂肪肝病细胞模型诱导液及其制备方法和应用 |
CN111603607B (zh) * | 2020-05-21 | 2021-01-05 | 武汉理工大学 | 一种以丝素为模板诱导获得的丝素-磷酸氢钙复合物及其制备方法 |
CN114028330B (zh) * | 2021-03-22 | 2023-03-31 | 南京艾德加生物制药科技有限公司 | 一种盐酸丙卡特罗口服溶液 |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047428A (en) * | 1988-06-16 | 1991-09-10 | Ss Pharmaceutical Co., Ltd. | Expectorant comprising hydroxyalkylcysteine derivative |
JPH0687748A (ja) * | 1991-12-18 | 1994-03-29 | Chugai Pharmaceut Co Ltd | 鎮咳去痰剤 |
JPH06239744A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH06239763A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
EP0998926A1 (en) * | 1997-07-16 | 2000-05-10 | SSP Co., Ltd. | Oral preparation comprising S-(3-hydroxypropyl)-L-cysteine |
JP2000169378A (ja) * | 1998-12-10 | 2000-06-20 | Taisho Pharmaceut Co Ltd | 咽頭疾患用組成物 |
JP2001233765A (ja) * | 2000-02-24 | 2001-08-28 | Ss Pharmaceut Co Ltd | 感冒薬 |
-
2002
- 2002-05-24 WO PCT/JP2002/005041 patent/WO2002096405A1/ja not_active Application Discontinuation
- 2002-05-24 CA CA002448068A patent/CA2448068A1/en not_active Abandoned
- 2002-05-24 CN CNB02810661XA patent/CN1293867C/zh not_active Expired - Fee Related
- 2002-05-24 KR KR10-2003-7015166A patent/KR20030097892A/ko not_active Application Discontinuation
- 2002-05-24 US US10/477,755 patent/US20040147605A1/en not_active Abandoned
- 2002-05-24 JP JP2002592916A patent/JP4365106B2/ja not_active Expired - Lifetime
- 2002-05-24 EP EP02726486A patent/EP1391200A4/en not_active Withdrawn
- 2002-05-24 TW TW091111107A patent/TW589177B/zh not_active IP Right Cessation
-
2005
- 2005-02-24 HK HK05101542A patent/HK1068812A1/xx not_active IP Right Cessation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5047428A (en) * | 1988-06-16 | 1991-09-10 | Ss Pharmaceutical Co., Ltd. | Expectorant comprising hydroxyalkylcysteine derivative |
JPH0687748A (ja) * | 1991-12-18 | 1994-03-29 | Chugai Pharmaceut Co Ltd | 鎮咳去痰剤 |
JPH06239744A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH06239763A (ja) * | 1993-02-18 | 1994-08-30 | Taisho Pharmaceut Co Ltd | 感冒薬 |
JPH08337532A (ja) * | 1995-06-14 | 1996-12-24 | Takeda Chem Ind Ltd | 医薬組成物 |
EP0998926A1 (en) * | 1997-07-16 | 2000-05-10 | SSP Co., Ltd. | Oral preparation comprising S-(3-hydroxypropyl)-L-cysteine |
JP2000169378A (ja) * | 1998-12-10 | 2000-06-20 | Taisho Pharmaceut Co Ltd | 咽頭疾患用組成物 |
JP2001233765A (ja) * | 2000-02-24 | 2001-08-28 | Ss Pharmaceut Co Ltd | 感冒薬 |
Non-Patent Citations (1)
Title |
---|
See also references of EP1391200A4 * |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPWO2007018190A1 (ja) * | 2005-08-10 | 2009-02-19 | 塩野義製薬株式会社 | 苦味抑制製剤 |
JP2007153877A (ja) * | 2005-11-11 | 2007-06-21 | Daiichi Sankyo Healthcare Co Ltd | 去痰剤を含有する医薬組成物 |
JP2013035869A (ja) * | 2005-11-11 | 2013-02-21 | Daiichi Sankyo Healthcare Co Ltd | 去痰剤を含有する医薬組成物 |
JP2013082754A (ja) * | 2005-11-24 | 2013-05-09 | Boehringer Ingelheim Internatl Gmbh | テルミサルタン及び利尿剤を含有する二層錠剤 |
JP2007197423A (ja) * | 2005-12-27 | 2007-08-09 | Daiichi Sankyo Healthcare Co Ltd | フドステインと抗コリン薬を含有する医薬組成物 |
JP2009001548A (ja) * | 2007-05-21 | 2009-01-08 | Daiichi Sankyo Healthcare Co Ltd | トレハロースからなる気道杯細胞過形成抑制剤。 |
Also Published As
Publication number | Publication date |
---|---|
JPWO2002096405A1 (ja) | 2004-09-09 |
CA2448068A1 (en) | 2002-12-05 |
EP1391200A4 (en) | 2004-06-16 |
KR20030097892A (ko) | 2003-12-31 |
JP4365106B2 (ja) | 2009-11-18 |
TW589177B (en) | 2004-06-01 |
HK1068812A1 (en) | 2005-05-06 |
US20040147605A1 (en) | 2004-07-29 |
CN1523984A (zh) | 2004-08-25 |
EP1391200A1 (en) | 2004-02-25 |
CN1293867C (zh) | 2007-01-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002096405A1 (fr) | Preparations de medicaments | |
JP4365107B2 (ja) | 医薬組成物 | |
US20100285164A1 (en) | Orally Disintegrating Excipient | |
KR20090113777A (ko) | 불쾌한 맛을 은폐한 경구 조성물 | |
KR20090020561A (ko) | 필름 피복된 고체 투여 형태 | |
KR20100051850A (ko) | 레바미피드를 함유하는 의약 조성물 | |
JP5259880B2 (ja) | 経口剤 | |
WO2016051782A1 (ja) | 苦味を有する薬剤の苦味をマスキングした経口投与製剤 | |
KR100957731B1 (ko) | 쓴맛이 저감된 프란루카스트 수화물을 함유하는 제제 | |
JP2007131561A (ja) | 経口固形製剤及びその製造法 | |
JP3899522B2 (ja) | 苦味が低減されたプランルカスト水和物を含有する製剤 | |
WO2005029980A1 (ja) | システイン類の不快な臭気又は味が軽減された組成物 | |
JP2004269513A (ja) | 固形製剤 | |
JP2021017445A (ja) | フェキソフェナジンを含有する医薬組成物 | |
JP2005162713A (ja) | 内服用組成物 | |
JP2019011306A (ja) | 医薬組成物 | |
JP2004091420A (ja) | 内服用医薬組成物 | |
JP2021017444A (ja) | オロパタジン及びカフェインを含有する医薬組成物 | |
JP2021017446A (ja) | フェキソフェナジン及びトラネキサム酸を含有する医薬組成物 | |
EP4308094A1 (en) | Coated solid pharmaceutical preparation | |
JP2022027636A (ja) | 安定化方法 | |
WO2020209350A1 (ja) | 糖尿病治療用口腔内速崩壊錠 | |
JP2011068614A (ja) | ビタミン製剤 | |
JP2023105116A (ja) | オロパタジンを含有する医薬組成物 | |
JP2023119588A (ja) | ロキソプロフェンとグリシンを含有する固形製剤及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002592916 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020037015166 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2448068 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10477755 Country of ref document: US Ref document number: 02810661X Country of ref document: CN Ref document number: 2002726486 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2002726486 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002726486 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |